Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver
Cells · 2024
DOI: 10.3390/cells13090756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Biki Gupta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Disease Progression, Integrins, Liver. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Integrin α4β7+ T cells perpetuate tissue injury in chronic inflammatory diseases, yet their role in hepatic fibrosis progression remains poorly understood. Here, we report increased accumulation of α4β7+ T cells in the liver of people with cirrhosis relative to disease controls. Similarly, hepatic fibrosis in the established mouse model of CCl4-induced liver fibrosis was associated with enrichment of intrahepatic α4β7+ CD4 and CD8 T cells. Monoclonal antibody (mAb)-mediated blockade of α4β7 or its ligand mucosal addressin cell adhesion molecule (MAdCAM)-1 attenuated hepatic inflammation and prevented fibrosis progression in CCl4-treated mice. Improvement in liver fibrosis was associated with a significant decrease in the infiltration of α4β7+ CD4 and CD8 T cells, suggesting that α4β7/MAdCAM-1 axis regulates both CD4 and CD8 T cell recruitment to the fibrotic liver, and α4β7+ T cells promote hepatic fibrosis progression. Analysis of hepatic α4β7+ and α4β7- CD4 T cells revealed that α4β7+ CD4 T cells were enriched for markers of activation and proliferation, demonstrating an effector phenotype. The findings suggest that α4β7+ T cells play a critical role in promoting hepatic fibrosis progression, and mAb-mediated blockade of α4β7 or MAdCAM-1 represents a promising therapeutic strategy for slowing hepatic fibrosis progression in chronic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
- Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA 15261, USA.
- Division of Anatomic Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
ORCID-Profile: Ravi Prakash Rai, Silvia Liu, Satdarshan P Monga
Förderung
- NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health
- NIH/NIDDK Digestive Disease Research Core Center
Zitieren
APA
Gupta, B., Rai, R. P., Pal, P. B., Rossmiller, D., Chaudhary, S., Chiaro, A., Seaman, S., Singhi, A. D., Liu, S., Monga, S. P., Iyer, S. S., & Raeman, R. (2024). Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver. Cells. https://doi.org/10.3390/cells13090756
Vancouver
Gupta B, Rai RP, Pal PB, Rossmiller D, Chaudhary S, Chiaro A, et al. Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver. Cells. 2024. doi:10.3390/cells13090756
BibTeX
@article{Gupta2024,
author = {Gupta, Biki and Rai, Ravi Prakash and Pal, Pabitra B and Rossmiller, Daniel and Chaudhary, Sudrishti and Chiaro, Anna and Seaman, Shannon and Singhi, Aatur D and Liu, Silvia and Monga, Satdarshan P and Iyer, Smita S and Raeman, Reben},
title = {Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13090756}
}
EUVIMED